Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia Sells 1,678 Shares of Stock

Cencora, Inc. (NYSE:COR) EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cencora Trading Down 0.0 %

Shares of COR traded down $0.05 during midday trading on Monday, hitting $227.64. The stock had a trading volume of 940,758 shares, compared to its average volume of 1,386,326. Cencora, Inc. has a fifty-two week low of $202.43 and a fifty-two week high of $253.27. The business has a 50-day simple moving average of $239.00 and a two-hundred day simple moving average of $234.13. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The firm has a market cap of $44.00 billion, a P/E ratio of 30.31, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.97%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

Institutional Trading of Cencora

A number of hedge funds have recently modified their holdings of COR. State Street Corp boosted its holdings in shares of Cencora by 3.8% during the third quarter. State Street Corp now owns 8,045,896 shares of the company’s stock worth $1,810,970,000 after purchasing an additional 291,867 shares during the period. Wellington Management Group LLP raised its holdings in shares of Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock worth $1,168,927,000 after acquiring an additional 338,452 shares in the last quarter. Geode Capital Management LLC boosted its position in Cencora by 4.7% during the third quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company’s stock valued at $941,183,000 after purchasing an additional 189,054 shares during the last quarter. Pacer Advisors Inc. grew its stake in Cencora by 6,855.3% in the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock valued at $464,874,000 after purchasing an additional 2,035,679 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Cencora by 3.7% in the 2nd quarter. Legal & General Group Plc now owns 1,875,445 shares of the company’s stock worth $422,538,000 after purchasing an additional 67,287 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on COR shares. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Finally, Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.